Kalbe Farma Tbk PT operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kalbe Farma Tbk PT with three other
pharmaceutical manufacturers in Asia:
Sawai Pharmaceutical Co., Ltd.
sales of 168.07 billion Japanese Yen [US$1.53 billion]
of which 80%
Harbin Pharmaceutical Group Company Limited
(10.81 billion Chinese Renmimbi [US$1.55 billion]
of which 65%
was Medicine Trade), and
Chongqing Taiji Industry (Group)
based in China
(10.69 billion Chinese Renmimbi [US$1.53 billion]
of which 74%
Kalbe Farma Tbk PT reported sales of 21.07 trillion Indonesian Rupiahs (US$1.54 billion)
December of 2018.
increase of 4.4%
versus 2017, when the company's sales were 20.18 trillion Indonesian Rupiahs.
Sales at Kalbe Farma Tbk PT have increased during each of the previous five years
(and since 2013, sales have increased a total of 32%).
Sales of Distribution and Logistics saw an increase
6.8% in 2018, from
5.97 trillion Indonesian Rupiahs to 6.38 trillion Indonesian Rupiahs.